Lulu Sun, MD, PhD

Pathology

Specializes in

Breast pathology, gynecologic pathology, molecular pathology

Appointments

Experience

Academic Title(s)

Associate Professor, Pathology and Immunology
Anatomic and Molecular Pathology

Publications & Research

View research profile »

Education

Fellowship: Gynecologic and Breast Pathology

2021 Washington University in St. Louis, St. Louis, MO

Residency: Anatomic Pathology

2020 Washington University in St. Louis, St. Louis, MO

Fellowship: Molecular Genetic Pathology

2019 Washington University in St. Louis, St. Louis, MO

Medical Degree

2016 Washington University in St. Louis, St. Louis, MO

PhD: Immunology

2016 Washington University in St. Louis, St. Louis, MO

Financial Disclosures
  • AstraZeneca
    • Consulting/Advisory Board: $10,000 - $19,999
    • Speaker Fees: $1 - $9,999
    • Reporting Date: 05/01/2026
  • Pairidex Inc.
    • Equity: Yes
    • Reporting Date: 05/01/2026

Washington University and its physicians and health professionals are committed to ensuring integrity and objectivity in medical decision-making. Some of our physicians and health professionals work collaboratively with pharmaceutical, medical device or other medical care related companies to develop innovative ideas and products that can improve health care delivery and clinical outcomes for patients. In some instances, our physicians and health professionals have an ownership or potential ownership interest in a commercial company; and/or are paid by a commercial company to provide advice on product design or to speak about the use of medications, devices, equipment or procedures. These payments may include: a) compensation for consulting and speaking engagements, b) equity, and/or c) royalties for products invented by our faculty. Any payments to Washington University physicians or health professionals must be based on tangible services and may not exceed fair market value for their work. In addition to disclosure on this website, physicians and health professionals earning more than $10,000 per year must disclose their corporate financial relationship in writing to patients when prescribing or using that company's products.

Is this your profile? Request an edit »